Hope in the Pipeline

Discover exciting new developments at Preferred Research Partners, including our new IV infusion suite, expanded clinical trial capabilities, and the introduction of Dr. David Weed to the team.

Have you or a loved one experienced ongoing abdominal pain, fatigue, or digestive issues like diarrhea or loss of appetite? You may be living with one of the lifelong conditions known as Inflammatory Bowel Disease (IBD), which includes Crohn’s disease and ulcerative colitis. In this episode of Hope in the Pipeline, Dr. Paul Wylie, Medical Director of Preferred Research Partners in Little Rock, Arkansas, welcomes Dr. Natasa Jensen to discuss what causes IBD, its symptoms, treatment options, and the importance of early diagnosis and clinical research. You’ll also meet Erik Guzman, a bilingual research coordinator, who shares his inspiring story and efforts to make clinical trials more accessible to the Spanish-speaking community. He discusses barriers to participation, the need for diversity in medical research, and how Preferred Research Partners is building trust and partnerships across Arkansas to create healthier, more informed communities.

For this episode of Hope in the Pipeline, Dr. Wylie is joined by one of our Clinical Research Coordinators, Jessica Watson. They talk about gastroparesis clinical trials, and Jessica explains what a research trial looks like. Interested in learning more? Visit our website for more information about clinical research trials: www.preferredresearchpartners.com

Gastroparesis affects about 5 million people in the U.S. — causing nausea, stomach pain, bloating, and more. In this episode of Hope in the Pipeline, Dr. Paul Wy shares how clinical trials are leading the way to better treatments and why participation matters. Together, we can bring hope to millions.

Welcome to the third part of our Hope in the Pipeline series on hypersomnolence disorders. In this episode, we dive deep into:   🔹 Medications used to treat narcolepsy – from older stimulants to newer, longer-lasting options 🔹 The role of antidepressants and sodium oxybate in managing symptoms like cataplexy 🔹 Key differences between narcolepsy and idiopathic hypersomnia (IH) 🔹 Current treatment options for IH and why diagnosis can be so challenging 🔹 Exciting ongoing clinical research at Preferred Research Partners, including a new potential therapy targeting narcolepsy and IH

Welcome back to Hope in the Pipeline! In this episode, we continue our deep dive into narcolepsy, exploring: ✅ What causes cataplexy (sudden loss of muscle tone) ✅ How dream sleep paralysis can leak into wakefulness ✅ Vivid sleep-related hallucinations and automatic behaviors ✅ The detailed diagnostic process for narcolepsy, including sleep studies and genetic testing ✅ How narcolepsy impacts daily life, work, and education ✅ Important ADA protections and reasonable accommodations for people with narcolepsy Narcolepsy is often misunderstood, but with the right knowledge, treatment, and support, people living with it can thrive. If you found this helpful, please like, share, and subscribe for more conversations on sleep health and neurological conditions. 📌 Stay tuned for Part 3 of our hypersomnolence series!

Have you ever felt overwhelmingly sleepy even after a full night’s rest? Narcolepsy and idiopathic hypersomnia are two central disorders of hypersomnolence that affect millions worldwide — often undiagnosed. In this episode of Hope in the Pipeline, we explore: 🧠 What narcolepsy and idiopathic hypersomnia are 🧠 Key symptoms and differences between the two 🧠 Causes, diagnosis, and treatment options 🧠 The role of the immune system in narcolepsy 🧠 How current clinical trials and research are bringing hope for better therapies Narcolepsy is a lifelong neurological disorder caused by the loss of hypocretin (orexin), leading to uncontrollable sleepiness, cataplexy, and fragmented nighttime sleep. Idiopathic hypersomnia, on the other hand, can leave people excessively sleepy even after 10+ hours of rest. If you or someone you know struggles with unexplained sleepiness, this video will help you understand these conditions and where research is headed. 👉 Don’t forget to like, share, and subscribe to Hope in the Pipeline for more episodes on rare and underrecognized conditions.

Did you know that the number of blood pressure medications you take could be a sign of untreated obstructive sleep apnea? There is a strong connection between obstructive sleep apnea (OSA) and hypertension, including the serious health risks of untreated OSA—from stroke and dementia to heart failure and even death. In this episode, Dr. Paul Wylie discusses a new clinical trial testing a promising medication designed to treat BOTH sleep apnea and high blood pressure. ✅ Learn the warning signs ✅ Understand the science ✅ Hear how you can make a difference through clinical research #sleepapnea #hypertension #sleepmedicine #sleepstudy #obstructivesleepapnea

Did you know that 12% of women experience chronic or episodic migraines, and for many, they’re tied to hormonal cycles? In this episode of Hope in the Pipeline, Dr. Paul Wylie dives into the causes, symptoms, and treatments of menstrual migraines. 🧠In this episode, you’ll learn: What causes menstrual migraines (hint: estrogen & hormone changes) How they differ from common migraines Why they often respond poorly to current medications What symptoms to look for, and how to track them Why clinical trials matter—and how YOU can get involved   💊 About the Clinical Trial: Open to individuals 18 years and older 18-week study, with the option for a 1-year extension Medication is taken just 7 days a month to help prevent migraines Compensation provided, plus free medication during the extension period if it helps   🧪 This trial is testing a promising FDA-approved treatment for menstrual migraines

In this episode of Hope in the Pipeline, Dr. Paul Wylie dives deep into chronic insomnia disorder—what causes it, how it affects both children and adults, and the latest research aimed at treating it. 🧠 Learn about: The types of insomnia symptoms Differences in diagnosing pediatric vs. adult insomnia Behavioral vs. pharmacological treatments The real-life impact of chronic sleep disruption Two new clinical trials are now enrolling participants (ages 10–17 and 18–65) Why your participation could help shape the future of insomnia treatment 📚 Plus: We're giving away 3 copies of Dr. Richard Ferber’s Solving Your Child’s Sleep Problems!   #Insomnia #SleepMedicine #ChronicInsomnia #clinicaltrials #clinicalstudy #sleepresearch

Attention Deficit Hyperactivity Disorder (ADHD) affects millions of children — but early diagnosis and the right treatment can make a world of difference. In this episode of Hope in the Pipeline, Dr. Paul Wylie, Neuropsychiatry and Sleep Medicine Specialist, explores the symptoms, causes, and treatment options for pediatric ADHD. We also dive into an exciting new clinical research trial for children ages 4 to 5 years and 7 months, testing a non-controlled medication already approved for older children and adults. This trial could help shape the future of ADHD treatment — and eligible families may receive a formal diagnosis and compensation for participation. Learn how ADHD presents differently in boys and girls, the role of genetics and sleep, and why your child’s struggles might have a biological solution. 📍 Visit PreferredResearchPartners.com to learn more or apply for the study. 🔔 Don’t forget to like, share, and subscribe for more episodes on mental health breakthroughs.

In this episode of Hope in the Pipeline, Dr. Paul Wylie discusses pediatric migraines, their prevalence, symptoms, and treatment options. He highlights the importance of understanding how migraines affect children differently than adults and the potential for clinical trials to improve treatment outcomes. The conversation emphasizes the need for awareness and research in managing pediatric migraines effectively.

In this episode of Hope in the Pipeline, Dr. Paul Wylie sheds light on narcolepsy—a complex neurological sleep disorder marked by overwhelming daytime sleepiness and sudden muscle weakness known as cataplexy. He breaks down the different types of narcolepsy, explores its symptoms, and dives into the science behind it, from genetic links to autoimmune triggers. The conversation also highlights current treatment options and promising clinical trials that aim to improve the quality of life for those living with this challenging condition.   #narcolepsy  #sleepdisorder #clinicaltrials #sleepmedicine

#ShiftWork #SWSD #SleepDisorder   Millions of workers rely on shift work to keep essential services running, but at what cost? Dr. Paul Wylie, a Neuropsychiatry and Sleep Medicine Specialist, dives into Shift Work Sleep Disorder (SWSD)—its impact on sleep, productivity, and long-term health risks like mood disorders, diabetes, and even cancer. Preferred Research Partners is currently enrolling participants for a 12-week clinical trial testing a medication that may improve alertness, cognitive function, and workplace safety for shift workers. 📞 501-553-9987 🌐 www.PreferredResearchPartners.com If you or someone you know struggles with shift work-related sleep issues, watch, share, and subscribe for more sleep health insights. #ShiftWork #SWSD #SleepDisorder #NightShift #CircadianRhythm #SleepOptimization #WorkLifeBalance #psychadelics #mentalhealth #mentalhealthawareness

An in-depth exploration of social anxiety disorder and generalized anxiety disorder, discussing their symptoms, prevalence, and the impact they have on individuals' lives. Dr. Paul Wylie shares insights into the causes, treatment options, and the importance of clinical trials in advancing mental health care. The discussion highlights the innovative treatments being tested to improve the quality of life for those affected.

This conversation explores the emerging field of psychedelic research in mental health, focusing on the potential of psychedelic medications to treat mood disorders. Dr. Paul Wylie, a neuropsychiatrist, discusses the historical context of mental health treatments, the evolution of psychedelics in therapy, and the mechanisms by which they may promote neuroplasticity and improve mental health outcomes. Katie Walker, a therapist and participant in a clinical trial, shares her personal experiences and insights into the therapeutic process, emphasizing the importance of safety and integration in treatment. This conversation delves into the evolving landscape of psychedelic therapy, focusing on the therapeutic toolbox available to clients, the future of psychedelic treatments, safety measures in clinical trials, and the financial aspects of participation in these studies. The speakers emphasize the importance of collaboration between therapists and clinical researchers to optimize the therapeutic experience while ensuring participant safety and rights.